Biology Reference
In-Depth Information
take into account modulation of the cAMP-pathway, as well as the combination of
active agents (e.g., combining a PDE5 inhibitor and a NO donor or NO-independent
activator of the soluble guanylyl cyclase) to affect multiple peripheral intracellular
targets. It is assumed that PDE inhibitors will be efficacious in terms of promoting
normal organ function and exert limited systemic adverse events.
References
Andersen JT, Ekman P, Wolf H, Beisland HO, Johansson JE, Kontturi M, Lehtonen T, Tveter K
(1995) Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year
placebo-controlled study. Urology 46:631-637
Andersson KE (2008) How many drugs for LUTS due to BPH are too many? J Urol 180:
811-812
Andersson KE, Chapple C, Wein A (2001) The basis for drug treament of the overactive bladder.
World J Urol 19:294-298
Antoni FA (2000) Molecular diversity of cAMP signaling. Front Neuroendocrinol 21:103-132
Becker AJ, Stief CG, Meyer M, Truss MC, Forssmann WG, Jonas U (1998) The effect of the
specific phosphodiesterase 4 inhibitor rolipram on the ureteral peristalsis in vitro and in vivo.
J Urol 160:920-925
Cahn D, Melman A, Valcic M, Christ GJ (1997) Forskolin: a promising new adjunct to intraca-
vernous pharmacotherapy. J Urol 155:1789-1794
Chiricos TN, Sanford E (1996) Cost consequences of surveillance, medical management or
surgery for benign prostatic hyperplasia. J Urol 155:1311-1316
Conti M, Jin SL (1999) The molecular biology of cyclic nucleotide phosphodiesterases. Prog
Nucleic Acid Res Mol Biol 63:1-38
Eardly I, Cartledge J (2002) Tadalafil (CIALIS) for men with erectile dysfunction. Int J Clin Pract
56:300-304
Emmick JT, Stuewe SR, Mitchell M (2002) Overview of the cardiovascular effects of tadalafil. Eur
Heart J 4(suppl H):H32-H47
Essayan DM (2001) Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 108:671-680
Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I, Soderling S, Hetman J, Beavo JA,
Philips SC (2000) Molecular cloning and characterization of a distinct human phosphodiester-
ase gene family: PDE11A. Proc Natl Acad Sci USA 97:3702-3707
Fink HA, McDonald R, Rutks IR, Nelson DB, Wilt TJ (2002) Sildenafil for male erectile
dysfunction: a systematic review and meta-analysis. Arch Intern Med 162:1349-1360
Fisher AD, Smith JF, Pillar JS, St Denis S, Cheng JB (1998a) Isolation and characterization of
PDE8A, a novel cAMP-specific phosphodiesterase. Biochem Biophys Res Commun
246:570-577
Fisher AD, Smith JF, Pillar JS, St Denis S, Cheng JB (1998b) Isolation and characterization of
PDE9A, a novel cGMP-specific phosphodiesterase. J Biol Chem 273:15559-15564
Gacci M, del Popolo G, Macchiarella A, Celso M, Vittori G, Lapini A, Serni S, Sandner P, Maggi
M, Carini M (2007) Vardenafil improves urodynamic parameters in men with spinal cord
injury: results from a single dose, pilot study. J Urol 178:2040-2043
Glina S, Toscano I, Gomatzky C, de Goes PM, Junior AN, Claro JF, Pagani E (2009) Efficacy and
tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical
trial. J Sex Med 6:553-557
Gratzke C, Uckert S, Kedia G, Reich O, Schlenker B, Seitz M, Becker AJ, Stief CG (2007) In vitro
effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth
muscle: a basic research approach. Urol Res 35:49-54
Search WWH ::




Custom Search